Why the study?
Does fulminant myocarditis following COVID-19 infection have a different clinical course and mortality compared to that following COVID-19 vaccination?
Does fulminant myocarditis following COVID-19 infection have a different clinical course and mortality compared to that following COVID-19 vaccination?
Fulminant myocarditis following COVID-19 infection has a more malignant clinical course than post-vaccination myocarditis, though both carry a similarly high mortality rate.
Answers are grounded in this paper and cite their sources.
Infection-associated fulminant myocarditis warrants closer hemodynamic monitoring and earlier support; confirms more malignant course than post-vaccination cases despite similar mortality.
In the first series to retrospectively assess fulminant myocarditis associated with COVID-19 infection versus COVID-19 vaccination, we found that both conditions had a similarly high mortality rate, while COVID-19 FM had a more malignant course with more symptoms on presentation, more profound hemodynamic decompensation (higher heart rate, lower blood pressure), more cardiac arrests, and higher temporary MCS requirements including VA-ECMO. In terms of pathology, there was no difference in most biopsies/autopsies that demonstrated lymphocytic infiltrates and some eosinophilic or mixed infiltrates. There was no predominance of young males in COVID-19 vaccine FM cases, with male patients representing only 40.9% of the cohort.
No takes yet. Share an insight, caveat, or question.
Guglin et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: